agilon health (AGL) drew fresh investor attention after reporting first quarter 2026 results, with revenue of US$1,420.46 million, higher net income of US$48.92 million, and raised full year revenue guidance.

The earnings beat and raised guidance have coincided with a sharp shift in sentiment, with a 30 day share price return of 204.06% and a very large 90 day gain, even though the 3 year total shareholder return is still down 85.04%.

If agilon health’s move has you rethinking where growth could come from next, it might be worth scanning other healthcare AI opportunities through our 32 healthcare AI stocks

With the stock up very sharply in a short period, yet still carrying an intrinsic value estimate that points to a 71.20% discount, is there genuine upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 315.5% Overvalued

At a last close of $81.73 against a narrative fair value of $19.67, the most followed valuation storyline paints a sharply different picture to the current market price.

The analysts have a consensus price target of $19.67 for agilon health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $37.5, and the most bearish reporting a price target of just $6.25.

Want to see what kind of earnings path and margin reset would need to sit behind that lower fair value, and how modest revenue growth assumptions still feed into the model? The narrative leans heavily on a specific profit margin destination, a compressed future P/E and a discount rate that quietly does a lot of the heavy lifting in today’s dollar terms.

Result: Fair Value of $19.67 (OVERVALUED)

However, there is still meaningful execution risk, with ongoing losses of US$373.54 million and pressure on medical margins potentially challenging the earnings path behind that 315.5% overvaluation call.

Another View: Cash Flows Point in the Opposite Direction

Those analyst targets paint agilon health as 315.5% overvalued at $81.73 versus a $19.67 fair value, yet the SWS DCF model points the other way, with the stock trading about 71.2% below an estimate of future cash flow value at $283.76. Which story do you think fits the risk and execution hurdles better?

Next Steps

If this mix of optimism and concern feels conflicting, treat it as your cue to act promptly, review the numbers yourself, and weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist with other opportunities that could fit your goals and risk comfort.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations using the 50 high quality undervalued stocks.
• Strengthen your focus on financial resilience by reviewing stocks highlighted in the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by checking out the screener containing 22 high quality undiscovered gems before everyone else starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.